SGLT2 inhibitors and chronic complications of diabetes mellitus

Abstract:

 SGLT2 inhibitors are a new class of oral diabetic medications for the treatment of type 2 diabetes. Over the last two years, results from large clinical trials on the cardiovascular safety of empagliflozin and canagliflozin have been published, while the safety study of dapagliflozin is still ongoing. Since 2015, when the results from the EMPA-REG OUTCOME study provided evidence that empagliflozin decreases CV mortality, and in June 2017 when the CANVAS program results were presented in San Diego on patients treated with canagliflozin, there has been a great attention payed on researching so called “class-effect“ of these medicines. Although current analyses suggest that these medicines share several notable characteristics, differences certainly exist and are not negligible. 

Key words:
cardiovascular mortality; class effects; diabetes mellitus type 2; SGLT2-inhibitors